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BRONCHIOLOALVEOLAR 
CARCINOMA 
Bronchioloalveolar carcinoma is a subtype of adenocarcinoma of the lung 
with a relatively better prognosis. We reviewed the cases of 50 consecutive 
patients with bronchioloalveolar carcinoma treated uring a 10-year period 
and attempted to analyze factors related to prognosis. During the 10-year 
study period, the prevalence of bronchioloalveolar carcinoma relative to 
adenocarcinoma of the lung remained steady. The subjects included 32 
male and 18 female patients with mean ages of 64.7 years and 55.1 years, 
respectively (t7 = 0.0030). The preoperative radiographic findings included 
40 cases of localized and 10 cases of diffuse bronchioloalveolar carcinoma. 
The clinicopathologic TNM staging included 20 patients with stage I 
cancer, 4 with stage II cancer, 11 with stage II Ia cancer, 3 with stage I I Ib 
cancer, and 12 with stage IV cancer. Forty patients with clinical stage I, II, 
or I I I  disease underwent operation (operability 80%). The resectability rate 
was 90% (36 of 40). Thirty-four procedures were considered as curative. The 
overall cumulative survival at 5 years was 22.2% (46.4% for stage I). 
Different TNM stages howed significant differences in survival time (p = 
0.0001). The median survival times were 64.6 months for stage I, 48.0 
months for stage II, 24.7 months for stage IIIa, 9.0 months for stage IIIb, 
and 4.5 months for stage IV disease. The median survival time for localized 
bronchioloalveolar carcinoma was 27.5 months, and the median survival 
time for diffuse bronchioloalveolar carcinoma was 4.3 months (p = 0.0002). 
The median survival time for the curative resection group was 30.6 months, 
and the median survival time for the noncurative resection or nonresection 
group was 5.8 months (p = 0.0001). On the basis of this study we conclude 
that (1) the prevalence of bronchioloalveolar carcinoma is quite steady, (2) 
bronchioloalveolar carcinoma presents at an earlier age in women, (3) 
bronchioloalveolar carcinoma frequently presents with lymphatic spread or 
systemic metastasis at diagnosis, (4) most localized bronchioloalveolar 
carcinomas are resectable and the prognosis with this type is better than 
that of the diffuse type, and (5) long-term survival correlates closely with 
initial roentgenographic appearance, TNM stage, and completeness of 
surgical resection. (J THORAC CARDIOVASC SURG 1995;110:374-81) 
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Taichung, Taiwan, Republic of China 
S ince its first description by Malassez 1 in 1876, bronchioloalveolar carcinoma (BAC) has been 
considered a multicentric tumor with a dismal prog- 
nosis. 2 Later studies, however, demonstrated that 
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most BACs occur as solitary pulmonary nodules. 35 
This has been further supported by recent re- 
ports.a, 7 Although numerous labels were attached 
to this tumor of uncertain origin, Leibow s in 1960 
was the first to describe the frequent association 
with the small peripheral airways and alveolar 
spaces and introduced the term bronchioloalveolar 
carcinoma. The multiple faces of BAC have been 
well described. 9 BAC, which presents as multiple 
foci pulmonary infiltrates, is frequently of the mu- 
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cin-secreting type, which bears a much worse prog- 
nosis than the nodular type) °
Characteristically, BAC advances by local inva- 
sion along the alveolar wall or undergoes aeroge- 
nous spread. The roentgenologic presentation may 
be expressed as a single pulmonary nodule, multiple 
pulmonary nodules, localized infiltrates, or even 
multiple loci infiltrates at different lobes. The latter 
pattern may be either synchronous or metachro- 
nous. Metastasis commonly involves both hematog- 
enous and lymphatic routes, s' 11 
We reviewed our experience with 50 consecutive 
patients with BAC treated during a 10-year period. 
The prevalence of BAC relative to adenocarcinoma 
of the lung was studied. In addition, the relation- 
ships between radiographic findings at diagnosis, 
completeness of resection, tumor staging, and prog- 
nosis were Jinvestigated to obtain determinants of 
survival in patients with BAC. 
Patients and methods 
Between January 1, 1983, and December 31, 1992, 1205 
patients with adenocarcinoma of the lung were admitted 
to Taichung Veterans General Hospital. Fifty consecutive 
cases of BAC were identified and the patients enrolled in 
this study. There were 32 male and 18 female patients. 
The mean age at diagnosis for male and female patients 
was 64.7 years and 55.1 years, respectively. The demo- 
graphic data of these patients are shown in Table I. 
The prevalence of BAC in relationship to adenocarci- 
noma of the lung was calculated for each individual year. 
The preoperative work-ups included plain chest film, 
fiberbronchoscopy, chest computed tomographic (CT) 
scan, liver sonography, whole body bone scan, and pulmo- 
nary function test to evaluate the possible ffectiveness of 
surgical therapy. To simplify the clinical classification, we 
divided the roentgenographic patterns of BAC into "lo- 
calized" and "diffuse" types. A solitary pulmonary nodule 
or mass was classified as localized BAC. An infiltrative 
type or multiple foci tumor was classified as diffuse BAC. 
Pathologic diagnosis of pulmonary malignancies was ob- 
tained in all patients. Cases with the focal area of BAC in 
adenocarcinoma of the lung were not unusual, and pa- 
tients with this finding were excluded from this study. 
The methods of diagnosis included pneumonectomy 
(3), bilobectomy (2), lobectomy (20), wedge resection 
(11), open lung biopsy (4), needle lung biopsy (6), and 
cytology (4). Forty patients, with clinical stages ranging 
from I to IIIa, underwent thoracotomy, and 36 pulmonary 
resections were done. All of the patients who receive 
operation also underwent mediastinal lymph node dissec- 
tion or sampling for nodal staging. A curative resection 
was defined when no gross or microscopic residual tumor 
remained. All of the current survivors have been followed 
up for more than 20 months. 
The surviwtl analysis by the Kaplan-Meier method 12 
and data comparison by the Lee-Desu statistical method 13 
Table I. Demographic data of 50 BAC cases 
Characteristics No. of patients 
Sex of patient 
Male 32 
Female 18 
X-ray findings 
Mass 40 
Infiltrative 10 
Location 
RUL 8 
RML 4 
RLL 5 
LUL 12 
LLL 8 
Multiple unilateral 4 
Multiple bilateral 9 
Diagnostic method 
Lobectomy 20 
Bilobectomy 2 
Pneumonectomy 3 
Wedge resection 11 
Open lung biopsy 4 
Needle biopsy 6 
Cytology 4 
Curative resection 
Yes 34 
No 16 
Stage 
I 20 
II 4 
IIIa 11 
IIIb 3 
IV 12 
Total 50 
RUL, Right upper lobe; RML, right middle lobe; RLL, right lower lobe; 
LUL, left upper lobe; LLL, left lower lobe. 
were done with the use of the SPSS/PC + Advanced 
Statistic 4.0 software package for microcomputer data 
management and analysis (SPSS Inc., Chicago, Ill.). 
Results 
Distribution of BAC. During the 10-year period, 
50 cases of BAC, among 1205 cases of adenocarci- 
noma of the lung, were encountered: a prevalence of 
4.1%. The annual occurrences of BAC ranged from 
1 to 8 (1.4% to 7.6% of overall adenocarcinoma of 
lung). The relationship between BAC and adenocar- 
cinoma is shown in Fig. 1. The prevalence of BAC 
during the most recent 4 years remained steady in 
the range of 4.1% to 4.6%. 
Gender and ages. There were 32 male and 18 
female patients. Their ages ranged from 22 to 76 
years. The mean age of male and female patients 
was 64.7 years (SD* 9.6) and 55.1 years (SD 10.5), 
*Standard eviation. 
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Fig. 1. Annual occurrence of BAC in relationship to adenocarcinoma (Aden-Ca) of lung during 10-year 
period. 
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Fig. 2. Overall cumulative survival curve in 50 cases of BAC with 5-year survival of 22.2%. pt., Patients; 
SE, standard error. 
respectively. Our data showed that the women were 
younger than the men at the time of diagnosis (p = 
0.0030). 
TNM stage. The clinicopathologic TNM staging 
of the disease included 20 patients with stage I 
disease, 4 stage II, 11 stage IIIa, 3 stage IIIb, and 12 
stage IV. The overall cumulative survival curve is 
shown in Fig. 2. The 5-year survival was 22.2%. The 
median survival times were 64.6 months for stage I, 
48.0 months for stage II, 24.7 months for stage IIIa, 
9.0 months for stage IIIb, and 4.5 months for stage 
IV. Fig. 3 shows the cumulative survival curves for 
different stages of BAC (p = 0.0001). The p values 
for the differences in survival times among the 
different stages are listed in Table II. Our data 
clearly demonstrated a better prognosis for stages I, 
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Fig. 3. Cumulative survival curves among different stages of BAC (p = 0.0001).pt., Patients; SE, tandard 
error. 
II, and IIIa BAC than for stage IV BAC. Compar- 
ison of the survival times for T1 NO M0 and T2 NO 
M0 BAC is shown in Fig. 4. T1 lesions tended to 
show a better outcome than T2 lesions (p = 0.0961). 
The current status of the patients, according to 
different stages, is listed in Table III. During the 
study period 34 patients died, 4 patients were lost to 
follow-up, and 12 patients urvived. 
Roentgenographic patterns. The preoperative 
roentgenographic presentations included 40 (80%) 
cases of localized BAC (mass/nodular lesions) and 
10 (20%) of diffuse BAC (multiple nodules or 
infiltrative lesions). The former group had a resec- 
tion rate of 82.5%, and the latter group had a 
resection rate of 30%. The median survival time was 
27.5 months for localized BAC and 4.3 months for 
diffuse BAC. Fig. 5 shows the cumulative survival 
curves according to the roentgenologic presenta- 
tions (p = 0.0002). 
Pulmonary resection. Ten patients in this study 
did not receive thoracotomy. Two of these were 
patients with stage I lung cancer who did not consent 
to surgical treatment. The other eight patients were 
Table II. p Values for different stages of BAC 
Stage 
H Ilia Illb IV 
Stage  
I 0 .8062 0 .1653 0 .0075 0 .0001 
I I  - -  0 .2583 0 .0339 0 .0109 
I I Ia  - -  - -  0 .0559 0 .0035 
I I Ib  - -  - -  - -  0 .5637 
not operated on because of distant metastasis. Forty 
patients with clinical stage I to IIIa lung cancer re- 
ceived exploratory thoracotomy. Thirty-six tumors 
were resected, and 34 of the procedures were consid- 
ered as curative. Two patients with stage IIIb disease 
who received surgical resection were categorized into 
the noncurative resection group because of gross re- 
sidual tumor. The median survival time was 30.6 
months for the curative resection group and 5.8 
months for the noncurative r section or nonresection 
group. Fig. 6 shows the cumulative survival curves 
according to the type of resection (p = 0.0001). The 
distribution of resection types for the different stages 
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Table IlL Current status of patients according to 
different stages 
Status 
Lost to 
Stage Dead Alive follow-up Total 
I 8 9 3 20 
II 3 0 1 4 
I I Ia 8 3 0 11 
IIIb 3 0 0 3 
IV 12 0 0 12 
Total 34 12 4 50 
of BAC is shown in Table IV. The p values for the 
difference in survival times among the different stages, 
after curative resection, are listed in Table V. 
Discussion 
BAC is a subtype of adenocarcinoma of thelung. 
It accounts for 1% to 9% of the total pulmonary 
malignancies.4,6, 14, 15 The cause of BAC is still 
unclear. Unlike small-cell and squamous cell carci- 
nomas of the lung, there is no definite link between 
BAC and smoking. 7 The pathologic architecture of 
BAC is similar to that of jaagsiekte disease in 
sheepa6-1s; however, only sporadic studies have sug- 
gested that BAC in human beings is related to the 
virus j9, 20 The cell origin may be either the type II 
pneumocyte (nonmucinous) or the Clara cell. 21-24 A 
familial recessive trait in BAC has been reported; 
however, this is unusualY 
Noninvasive procedures for diagnosis of BAC are 
unreliable. Roentgenographically, BAC is a great 
mimicker. It can present as a solitary pulmonary 
mass or nodule, focal pulmonary infiltrates, or mul- 
tiple loci pulmonary infiltrates, '9, 15 One study 
demonstrated that CT scan findings such as a star- 
like pattern, pseudocavitation, heterogeneous atten- 
uation, pleural tags, and air bronchogram are char- 
acteristic of BAC. 26 Most of our patients had a 
preoperative chest CT scan; however, all of the 
aforementioned clues for the diagnosis of BAC were 
incidental findings. 
One study demonstrated that BAC makes up 
an unusually high percentage (23.5%) 27 of total 
primary bronchogenic adenocarcinoma. However, 
more often BAC comprises only a small portion of 
the primary lung cancers. The overall proportion of 
BAC in bronchogenic adenocarcinoma in this insti- 
tute was 4.9%, which is consistent with that of other 
series. Moreover, this ratio was relatively constant 
during the most recent 4 years (ranging from 4.1% 
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to 4.6%). An increased incidence of BAC may result 
from improved recognition through better definition 
of the tumor. 
It is well known that nodular BAC bears a better 
prognosis than infiltrative BAC. The roentgeno- 
graphic appearance of BAC is closely related to the 
pathologic subtype of this tumor. Most of the nod- 
ular types of BAC are nonmucinous, and most of the 
infiltrative type are mucinous. The possible mecha- 
nism for different roentgenographic patterns and 
tumor spreading was well described by Ohori and 
colleagues 2 in 1992. In that study, BAC was divided 
into three subtypes: mucinous, nonmucinous, and 
sclerosing. The mucinous type tends to have high 
type IV collagen expression and low alpha-2 integrin 
receptors~ which predisposes the tumor cell to de- 
tach from the basement membrane. Aerogenous 
spreading is the consequence, and pulmonary infil- 
trate is the roentgenographic presentation. The scle- 
rosing type shows increased type IV collagenase 
activity, which will destroy the basement membrane 
and will facilitate spread of the tumor through the 
lymphatic duct. We simplified our classification i to 
localized :BAC and diffuse BAC for evaluation of 
prognosis. Ten of our patients (20%) had the diffuse 
type (bilateral or multiple pulmonary infiltrates). All 
of these patients had stage II disease or higher and 
only three patients (30%) received resection. The 
median survival time was 4.3 months. On the con- 
trary, 40 patients (80.0%) had the localized type 
(pulmonary nodule or mass), of which 33 (82.5%) 
underwent resection. The median survival time in 
this subtype was 27.5 months. Our data demonstrate 
that most localized BACs can be resected and that 
the survival is significantly higher than that of diffuse 
BAC (p = 0.0002). 
Daly and colleagues 6 reported a7.5% lymph node 
metastasis rate in BAC and concluded that BAC is 
more influenced by local neoplastic processes than 
by lymph node metastases. 6 However, only 20 pa- 
tients in this series had stage I disease. This was 
reflected by the 60% prevalence of lymph node or 
systemic metastasis at the time of diagnosis. Among 
the patients with stage I disease, six had stage T1 NO 
M0 and 14 had stage T2 NO M0 disease. The 5-year 
cumulative survivals for patients in these groups 
after curative resection were 83.3% and 25.7%, 
respectively (p -- 0.0961). The difference in survival 
times for these two groups was not significant, which 
may be related to a small sample size. Our experi- 
ence shows that in the majority of patients the 
disease is diagnosed in the late stage and lymph 
node and systemic metastases are common findings. 
As for the extent of surgical resection, one series 
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Table IV. Distribution of operative type among 
different stages of BAC 
Table V. p Values among different stages of BAC in 
the curative resection group 
Type of resection Stage 
Stage Curative Noncurative Total H 
I 18 2 20 Stage 
II 4 0 4 I 0.8075 
IIIa 11 0 11 II -- 
IIIb 0 3 3 IIIa --  
IV 1 11 12 
Total 34 16 50 
showed no difference in survivals for wedge resection 
and lobectomy for T1 group BAC. However, in a 
comparison of the surgical results for stage I BAC 
from two recent large series, the 5-year survivals were 
quite different (75.2% versus 55%). 6, 7 This discrep- 
ancy might be caused by understaging of the lung 
cancer in the series of Harpole and associates 7 because 
of inadequate lymph node staging. One large series 
from Japan showed that only 54.9% of the T1 lung 
cancers were free from lymph node involvement. 29 
These findings further support routine mediastinal 
lymph node dissection in lung cancer operations. 
In this series, 40 patients with stage I to stage Il ia 
disease underwent operation. Thirty-six patients 
(90%) underwent tumor resection, and the majority 
Ilia IV 
0.1911 0.0983 
0.2583 0.1573 
-- 0.1624 
of the operations were considered as curative 
(85%). All of the four unresectable cases of BAC 
involved clinical stage IIIa disease. Our resection 
rate was similar to that of previous reports. 6'7, 3o 
The median survival times in the groups with cura- 
tive and noncurative resection were 30.6 months and 
5.8 months, respectively (p = 0.0001). The results 
indicate that complete surgical resection provides 
the only chance for long-term survival. 
In conclusion, our data showed the following: 
(1) the prevalence of BAC was steady during the 
observation period, (2) BAC presented at an 
earlier age in women, (3) lymphatic spread and 
systemic metastasis were common findings, (4) 
most cases of localized BAC were resectable, and 
(5) long-term survival correlated with initial 
roentgenographic appearance, TNM stage, and 
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the completeness of surgical resection. The results 
indicate that most cases of BAC are diagnosed at 
a relatively late stage. However, if a curative 
surgical procedure can be done, a good chance for 
long-term survival still can be anticipated accord- 
ing to individualized TNM staging. 
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